These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21935305)

  • 1. Economic considerations in the treatment of invasive aspergillosis: a review of voriconazole pharmacoeconomic studies.
    Krueger KP; Nelson AC
    Clinicoecon Outcomes Res; 2009; 1():35-43. PubMed ID: 21935305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of voriconazole versus liposomal amphotericin B for primary therapy of invasive aspergillosis among patients with haematological disorders in Germany and Spain.
    Ostermann H; Solano C; Jarque I; Garcia-Vidal C; Gao X; Barrueta JA; De Salas-Cansado M; Stephens J; Xue M; Weber B; Charbonneau C
    BMC Pharmacol Toxicol; 2014 Sep; 15():52. PubMed ID: 25253630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Voriconazole: new preparation. Invasive aspergillosis: benefits to be confirmed.
    Prescrire Int; 2004 Feb; 13(69):13-6. PubMed ID: 15055210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
    Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
    J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
    Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
    Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
    Selleslag D; Vogelaers D; Marbaix S
    Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic evaluation of voriconazole in the treatment of invasive aspergillosis in the Netherlands.
    Jansen JP; Meis JF; Blijlevens NM; van't Wout JW
    Curr Med Res Opin; 2005 Oct; 21(10):1535-46. PubMed ID: 16238893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive aspergillosis: is treatment with "inexpensive" amphotericin B cost saving if "expensive" voriconazole is only used on demand?
    Garbino J; Schnetzler G; Roberts C
    Swiss Med Wkly; 2006 Sep; 136(39-40):624-30. PubMed ID: 17086508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole.
    Jeu L; Piacenti FJ; Lyakhovetskiy AG; Fung HB
    Clin Ther; 2003 May; 25(5):1321-81. PubMed ID: 12867215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
    Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
    Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.
    Rotstein C; Laverdière M; Marciniak A; Ali F
    Can J Infect Dis Med Microbiol; 2004 Sep; 15(5):277-84. PubMed ID: 18159506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Voriconazole : a review of its use in the management of invasive fungal infections.
    Scott LJ; Simpson D
    Drugs; 2007; 67(2):269-98. PubMed ID: 17284090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of voriconazole compared with conventional amphotericin B for the primary treatment of aspergillosis in immunocompromised patients.
    Wenzel R; Del Favero A; Kibbler C; Rogers T; Rotstein C; Mauskopf J; Morris S; Schlamm H; Troke P; Marciniak A
    J Antimicrob Chemother; 2005 Mar; 55(3):352-61. PubMed ID: 15728146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole: a broad-spectrum triazole for the treatment of invasive fungal infections.
    Cecil JA; Wenzel RP
    Expert Rev Hematol; 2009 Jun; 2(3):237-54. PubMed ID: 21082966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Economic evaluation of voriconazole versus amphotericin B in the treatment of invasive aspergilosis].
    Grau Cerrato S; Mateu-de Antonio J; Soto Alvarez J; Muñoz Jareño MA; Salas Sánchez E; Marín-Casino M; Rubio Terrés C
    Farm Hosp; 2005; 29(1):5-10. PubMed ID: 15773796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative cost-effectiveness of voriconazole and amphotericin B in treatment of invasive pulmonary aspergillosis.
    Greene RE; Mauskopf J; Roberts CS; Zyczynski T; Schlamm HT
    Am J Health Syst Pharm; 2007 Dec; 64(24):2561-8. PubMed ID: 18056944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic assessment of therapy for invasive aspergillosis.
    Luong ML; Husain S; Rotstein C
    Mycoses; 2013 May; 56(3):338-49. PubMed ID: 23311989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomics of voriconazole in the management of invasive fungal infections.
    Al-Badriyeh D; Heng SC; Neoh CF; Slavin M; Stewart K; Kong DC
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):623-36. PubMed ID: 21155694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis.
    Lewis JS; Boucher HW; Lubowski TJ; Ambegaonkar AJ; Day DL; Patterson TF
    Pharmacotherapy; 2005 Jun; 25(6):839-46. PubMed ID: 15927903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.